XCX.CN falls 50% to C$0.005 on CNQ Feb 13, 2026: selling pressure ahead

The XCX.CN stock plunged 50.00% to C$0.005 on the CNQ (Canada) during market hours on Feb 13, 2026, on a 718,971 share print versus an average of 21,026. Today’s move erased the previous close of C$0.01 and left the share price at the year low. The drop reflects thin liquidity, negative fundamentals and high short-term volatility in Greenrise Global Brands Inc. (XCX.CN), a Canadian healthcare firm supplying medical cannabis products to German pharmacies.

XCX.CN stock: Today’s price action and volume

XCX.CN stock traded at C$0.005 on CNQ with a -50.00% one‑day change and intraday range locked at C$0.005. Volume surged to 718,971, a relative volume of 34.19, indicating outsized selling interest compared with the 21,026 average.

The sharp one‑day fall pushed the price toward the 52‑week low of C$0.005 from a high of C$0.025. For active traders, the extreme flow and sub‑penny price create execution and liquidity risks.

XCX.CN stock: Fundamentals and valuation snapshot

Greenrise Global Brands Inc. (XCX.CN) shows weak fundamentals: market cap near C$258,277, EPS -0.03, and a negative PE of -0.17. The company reports negligible revenue per share and negative book value per share at -0.06 (TTM), signaling capital strain.

Enterprise value vastly exceeds market cap (EV C$2,857,114.95 shown in metrics), which highlights balance‑sheet distortion. The healthcare sector average metrics contrast sharply with XCX.CN’s numbers, underlining valuation stress and limited margin of safety for investors.

XCX.CN stock: Technicals, liquidity and trading risks

Technically, RSI around 47.31 and ADX 41.16 point to a strong trend with neutral momentum. The 50‑day average price is C$0.0063 and 200‑day average C$0.00603, both above or near today’s level, confirming a downtrend.

Low current ratio 0.00 and cash per share C$0.00021 mean working capital is minimal. Thin floats and high relvolume raise slippage and bid‑ask risk. Traders should expect large price gaps and low fill quality at these levels.

XCX.CN stock: Meyka AI rates and technical grade

Meyka AI rates XCX.CN with a score out of 100: Meyka AI rates XCX.CN with a score of 65.10 out of 100, Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

This proprietary grade sits alongside an independent company rating of D+ / Strong Sell dated Feb 10, 2026. Investors should treat the Meyka grade as a data point, not investment advice.

XCX.CN stock: Catalysts, news and peer context

Key catalysts include upcoming earnings announcement (previously scheduled May 30, 2025) and any regulatory or distribution updates in Germany. The firm operates in Drug Manufacturers – Specialty & Generic within Healthcare, a sector that has been underperforming year‑to‑date.

Compare competitor flows and listings Investing.com comparisons and broader cap table peers Investing.com compare link for context. Also see the Meyka stock page for live metrics: Meyka stock page.

XCX.CN stock: Practical trading takeaways and price targets

Given current liquidity and fundamentals, short‑term traders may use limit orders and tight risk controls. We set conservative price levels: short‑term resistance C$0.01, medium‑term target C$0.02, and downside stress floor near C$0.002 if selling continues.

These price targets reflect market microstructure and sector weakness. Any positive operational news or larger liquidity inflows would be required to sustainably lift the price toward our medium‑term target.

Final Thoughts

XCX.CN stock opened the market hours session on Feb 13, 2026, under significant selling pressure, closing at C$0.005 with volume 718,971 that far outstripped the average. Fundamentals are weak: negative EPS -0.03, negative book value and limited cash per share increase downside risk. Meyka AI’s forecast model projects a 12‑month price near C$0.019 (model‑based), which implies an upside of 280.00% versus today’s C$0.005, but forecasts are model‑based projections and not guarantees. Our view: XCX.CN remains high risk, suited to speculative traders who accept low liquidity and potential capital loss. For long investors, wait for clearer revenue improvement, stronger balance sheet metrics, or confirmed distribution wins in Germany before adding exposure. See supporting comparisons at Investing.com compare and the Meyka stock page for live updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.